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agomelatine is a cost-effective treatment of major depressive disorders compared to 
generics of sertraline and venlafaxine.
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OBJECTIVES: To evaluate a cost-utility of sertindole compared with commonly used 
antipsychotic drugs in Poland: haloperidol and risperidone in the treatment of general 
population of schizophrenic patients and with risperidone in a group of patients 
intolerant to at least one other antipsychotic agent. METHODS: Cost-utility Markov 
model was constructed in ﬁ ve-year time horizon. Clinical effectiveness was assessed on 
the basis of RCTs, meta-analyses, observational studies and systematic reviews. The 
measures of effectiveness in the CUA were quality adjusted life-years (QALY) and life-
years gained (LYG). Direct medical costs were calculated from perspective of two payers 
(Polish National Health Fund and patient). Cost of: oral antipsychotic treatment, inpa-
tient care, primary health care, specialist care and adverse events treatment (extrapyra-
midal symptoms, sedation and weight gain) were included. Discount rates of 5% for 
costs and 3.5% for beneﬁ ts were used. Utilities and disutilities associated with AEs and 
relapse were derived from published literature. RESULTS: In general population of 
schizophrenic patients cost per QALY/LYG gained, using sertindole instead of risperi-
done is 97,396/26,585 PLN (c22,507/6,144) respectively; cost per QALY/LYG gained, 
using sertindole instead of haloperidol, is 82,132/20,670 PLN (c18,980/4,777) respec-
tively. In population intolerant to at least one other antipsychotic agent sertindole 
dominates risperidone (sertindole is less expensive and more effective considering both 
QALY/LYG gained). The sensitivity analysis indicated the robustness of the results. 
Obtained results are placed below the acceptability threshold (3xGDP per capita in 
Poland) which is about 105,500 PLN (c24,380). The 2009 weighted average exchange 
rate of Polish National Bank was c1 = PLN 4.3273. CONCLUSIONS: Treatment of 
schizophrenia with sertindole is a cost-effective strategy in comparison with risperi-
done and haloperidol therapy. In a group of patients intolerant to at least one other 
antipsychotic agent sertindole compared to risperidone is dominant strategy.
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OBJECTIVES: A recent meta-analysis has shown that escitalopram, a selective inhibi-
tor of serotonin reuptake, is one of the best choices when starting a treatment of 
moderate to severe major depressive disorder (MDD), with a favourable balance 
between efﬁ cacy and tolerability. Our objective was to perform an economic evalua-
tion of escitalopram versus citalopram in Israel. Citalopram is available as a generic 
drug and is included in the National Health Basket. METHODS: A decision tree model 
was used to assess the cost-utility of escitalopram versus citalopram in ﬁ rst-line treat-
ment of MDD. The model also accounted for second-, third- and fourth-line treat-
ments for patients not responding to therapy, with an overall time horizon of 12 
months. The analysis adopted a Health Maintenance Organization perspective. The 
main outcomes were quality-adjusted life-years (QALYs) and costs associated with 
local health care resource use (including drug use, and hospitalizations due to depres-
sion or suicide attempt). One-way and two-way sensitivity analyses were performed 
with the following parameters: probabilities of remission after initial and subsequent 
treatment, probabilities of relapse, suicide attempt and suicide-related death, number 
of hospitalization days due to a suicide attempt, costs of initial and subsequent treat-
ments and utility values. In addition, we used a Monte Carlo simulation. RESULTS: 
Compared to citalopram, escitalopram was more effective in terms of QALYs at a 
small incremental cost. The average QALYs of patients treated with escitalopram and 
citalopram were 0.728 and 0.720 respectively. The average cost of patients treated 
with escitalopram and citalopram were c105 and c63 respectively. The incremental 
cost-utility ratio was c5,150 (NIS23,875) per QALY. The variation of remission rates 
had the most inﬂ uence on this ratio in the sensitivity analyses. CONCLUSIONS: This 
local economic evaluation shows that compared to citalopram, escitalopram should 
be the preferred option in depression in Israel with an acceptable cost per QALY.
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OBJECTIVES: The main objective was to evaluate the consumption of antidepres-
sants, it s utilization as the basic aspect of the quality of life and to analyze the using 
of the original drugs or generics and to show the pharmacoeconomical impact of this 
group of drugs considering to it s ﬁ nancial costingness. METHODS: We used the 
analysis of consumption trend of antidepressants and the analysis of the trend of prices 
of antidepressants. We compared the original and generic market with antidepressants 
in Slovakia, we monitored and compared the prices for DDD and we evaluate the impact 
of new generics on the prices of originals as well. RESULTS: The consumption of 
antidepressants has increased because of increasing number depression illnesses which 
could be continually treated by modern antidepressants since successful treatment 
depends on relaps prevention. Such outcome could be reached by usage of the latest 
antidepressants with good compliance (escitalopram, venlafaxine, mirtazapin). Since 
2005 the consumption (packages sold) of antidepressant increased by 29% whereas 
the sales value stagnated as result of declining price. The price for daily recommended 
dosage decreased by 52.7% (from c0.80 in 2001 to c0.38 in 2008). This was inﬂ u-
enced mainly by the increasing number of generics medicaments which pushed the 
price down. In 2009 the price of original antidepressants fall by 26.4% as reason of 
generic molecules. Based on long-term surveys the similar trend could be expected also 
in the future. CONCLUSIONS: The utilization of antidepressants lead to better 
quality of life. From the pharmacoeconomical view, the development of new molecules 
goes hand in hand with the decrease of invalidation, decrease of the cost for hospi-
talization, as well as increase people ‘s ability to take care about themselves. On the 
other hand, the generic substitution leads to increase of the amount of treated patients.
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OBJECTIVES: Evaluate health care utilization among depressed patients before and 
after initiating duloxetine. METHODS: Depressed adults treated with duloxetine 
during January 1, 2006-September 30, 2007 were identiﬁ ed from the General Practice 
Research Database. All-cause health care utilization in the 12-months before and after 
treatment initiation was compared for patients and for the subset of patients with 
pre-period unexplained pain (UPain). Generalized Estimating Equation models were 
used to identify factors associated with the pre-post differences in hospitalization rates. 
Covariates included age, gender, pre-period comorbid conditions and medication use. 
RESULTS: A total of 909 patients were identiﬁ ed (mean age = 49.6; female = 67.7%), 
and 45% experienced UPain. Three-quarters of patients were prescribed a SSRI and 
11% were untreated with antidepressants before initiating duloxetine. Among 
patients, the rate of hospitalization was higher in the pre-period compared to the 
post-period (20.7% vs.16.5%, p = 0.006). There were no signiﬁ cant pre-post differ-
ences in the rates of accident & emergency visits, specialist referrals, or analgesic use. 
Among patients with UPain, fewer were hospitalized (26.2% vs. 19.1%, p = 0.003) 
or received analgesic in the post-period (77.0% vs. 71.7%, p = 0.015). Multivariate 
analysis conﬁ rmed fewer patients experienced hospitalization after duloxetine initia-
tion. All depressed patients with pre-period anxiolytic use (OR = 0.70, 95% CI, 
0.50–0.97, p = 0.033) or UPain patients with pre-period anticonvulsant use (OR = 
0.44, 95% CI, 0.21–0.91, p = 0.026) experienced a decreased hospitalization rate after 
initiating duloxetine and the magnitude of change was larger than that for patients 
not receiving these medications. All depressed patients with pre-period alcohol/drug 
dependence (OR = 1.83, 95% CI, 1.01–3.30, p = 0.045) and sleep disorder (OR = 
1.65, 95% CI, 1.05–2.59, p = 0.031) had an increase in the hospitalization rate from 
the pre- to post-period, while those without the conditions had a decreased hospitaliza-
tion rate. CONCLUSIONS: Hospitalization rates were lower following duloxetine 
initiation among depressed patients. Pre-period alcohol/drug dependence, sleep disor-
ders, anxiolytic and anticonvulsant use were associated with the pre-post difference 
in the hospitalization rate.
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OBJECTIVES: The lifetime emotional, social, and ﬁ nancial consequences experienced 
by individuals with schizophrenia spectrum disorders have signiﬁ cant effects on their 
families. Therefore, it is essential to increase the knowledge and awareness of the 
informal caregiver burden. Here, the purpose was to study objective burden (time and 
money spent), as well as subjective burden (care-related quality of life) of informal 
caregivers to patients with schizophrenia spectrum disorders. METHODS: Patients 
with schizophrenia spectrum disorders and their closest informal caregivers were 
recruited and patient- and caregiver-related characteristics and variables related to the 
provision of formal care were assessed. The subjective burden was assessed using the 
CarerQol. The objective burden was assessed prospectively during four weeks with 
daily recordings by the caregiver using diaries of the money and time spent on the 
patient. Data was analyzed using descriptive statistics. RESULTS: One-hundred and 
seven patients (53% females; mean age 43 ± 11 years) from nine centers in Sweden, 
and 118 of their closest informal care-givers (67% females; mean age 58 ± 15 years) 
entered the study. The mean (standard deviation, SD) GAF for the patients was 52 
(11). Subjective burden (CarerQol VAS) correlated positively to GAF. The mean (SD) 
time spent on caring for relatives with schizophrenia spectrum disorders was 22 (36) 
hours per week. Half of this (11 hours) was “stand-by” time and another 5 hours 
were spent on household work. Caregivers’ mean (SD) monthly expenses in support 
